Johnson & Johnson (NYSE:JNJ) Shares Acquired by Prospera Private Wealth LLC

Prospera Private Wealth LLC lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 948.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,293 shares of the company's stock after purchasing an additional 47,306 shares during the quarter. Johnson & Johnson comprises about 1.6% of Prospera Private Wealth LLC's investment portfolio, making the stock its 13th biggest position. Prospera Private Wealth LLC's holdings in Johnson & Johnson were worth $8,475,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. Innealta Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth approximately $27,000. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after purchasing an additional 91 shares during the period. Morton Brown Family Wealth LLC grew its position in shares of Johnson & Johnson by 400.0% during the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock worth $41,000 after buying an additional 200 shares in the last quarter. Finally, MFA Wealth Advisors LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $43,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Daiwa America cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 23rd. Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a report on Wednesday, October 16th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $175.94.

Johnson & Johnson Trading Down 0.4 %

NYSE:JNJ traded down $0.67 during trading hours on Wednesday, hitting $152.33. The company had a trading volume of 3,840,888 shares, compared to its average volume of 7,010,478. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average of $160.83 and a 200 day moving average of $156.19. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a market cap of $366.75 billion, a P/E ratio of 22.09, a P/E/G ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $2.66 EPS. Sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.26%. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.